Navigation Links
Prostate cancer spurs new nerves
Date:12/1/2008

Prostate cancer and perhaps other cancers promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.

Previous research showed that prostate cancer follows the growth of nerves, but this is the first time that scientists have demonstrated that the tumors actually promote nerve growth.

"This is the first report of this phenomenon," said Dr. Gustavo Ayala, professor of pathology and urology at BCM and first author of the article. "It represents an important new target in prostate cancer treatment, as prostate cancers are more aggressive when neurogenesis is present."

Ayala noted that this finding is comparable to the discovery of angiogenesis or the growth of new blood vessels. Both are part of the wound repair process.

"We also believe that axongenesis and neurogenesis is found not only in prostate cancer, but is potentially a more global phenomenon, particularly relating to those cancers that grow along nerve paths," said Ayala, also a researcher in the Dan L. Duncan Cancer Center at BCM.

Ayala and his colleagues studied the neurogenesis in tissue culture, in human tissues of patients who had had prostate cancer and compared to prostate tissues from patients who had died of other ailments. They calculated the density of nerves in human prostate tissues, including those with prostate cancer. They found that nerve density was considerably higher in patients with prostate cancer and in precancerous lesions. As part of the study, he used an entire prostate gland to reconstruct the prostate and enable scientists to see the growth of nerves and axons in three-dimensions, a computerized process that took substantial continuous computer processing.

He and his colleagues have even identified a possible method of regulating the growth of new nerves and axons through a protein called semaphorin 4F. Semaphorins are embryologically active molecules that regulate nerve growth and direction. Most disappear in adults, but semaphoring 4F is active in wound repair. When prostate cancer cells overproduce semaphorin 4F, new nerves result. Blocking semaphoring 4F prevents the growth of new nerves.


'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related biology news :

1. Genetic risk factors may tailor prostate cancer screening approaches
2. Height linked to risk of prostate cancer development and progression
3. Why a common treatment for prostate cancer ultimately fails
4. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
5. UCLA researchers locate and image prostate cancer as it spreads to lymph nodes
6. Prostate cancer vaccines more effective with hormone therapy
7. Counting tumor cells in blood predicts treatment benefit in prostate cancer
8. Urologists identify 7 biomarkers that may help pinpoint prostate cancer recurrence
9. Certain form of tomatoes could be key to prostate cancer prevention
10. Estrogen helps drive distinct, aggressive form of prostate cancer
11. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology: